(Q39462851)

12 September 2017

title

The oncolytic adenovirus AdΔΔ enhances selective cancer cell killing in combination with DNA-damaging drugs in pancreatic cancer models (English)

1 reference

12 September 2017

1 reference

1 reference

1 reference

6

1 reference

12 September 2017

G Cherubini

1

1 reference

12 September 2017

C Kallin

2

1 reference

12 September 2017

A Mozetic

3

1 reference

12 September 2017

K Hammaren-Busch

4

1 reference

12 September 2017

H Müller

5

1 reference

12 September 2017

G Halldén

7

1 reference

12 September 2017

publication date

6 October 2011

1 reference

12 September 2017

1 reference

12 September 2017

volume

18

1 reference

12 September 2017

issue

12

1 reference

12 September 2017

page(s)

1157-1165

1 reference

https://scigraph.springernature.com/pub.10.1038/gt.2011.141

12 September 2017

exact match

0 references

cites work

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.141

Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.141

Recent progress in the battle between oncolytic viruses and tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.141

Oncolytic viral therapies - the clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.141

Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.141

Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.141

A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.141

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.141

China approves world's first oncolytic virus therapy for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.141

Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.141

Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.141

Phase II Trial of Intravenous CI-1042 in Patients With Metastatic Colorectal Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.141

a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.141

Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.141

Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.141

Adenovirus overrides cellular checkpoints for protein translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.141

E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.141

Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.141

A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.141

Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.141

Oncolytic adenovirus Ad5/3-delta24 and chemotherapy for treatment of orthotopic ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.141

Activity of the adenoviral E1A deletion mutant dl922-947 in ovarian cancer: comparison with E1A wild-type viruses, bioluminescence monitoring, and intraperitoneal delivery in icodextrin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.141

An E1B-19 kDa gene deletion mutant adenovirus demonstrates tumor necrosis factor-enhanced cancer selectivity and enhanced oncolytic potency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.141

Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.141

Oncolytic adenoviral mutants with E1B19K gene deletions enhance gemcitabine-induced apoptosis in pancreatic carcinoma cells and anti-tumor efficacy in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.141

Improved potency and selectivity of an oncolytic E1ACR2 and E1B19K deleted adenoviral mutant in prostate and pancreatic cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.141

Phase II trial of gemcitabine, irinotecan, and celecoxib in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.141

A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.141

Tumor necrosis factor-alpha induces Bax-Bak interaction and apoptosis, which is inhibited by adenovirus E1B 19K

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.141

E1B 19K blocks Bax oligomerization and tumor necrosis factor alpha-mediated apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.141

Comparison of molecular strategies for breast cancer virotherapy using oncolytic adenovirus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.141

Efficacy of oncolytic mutants targeting pRb and p53 pathways is synergistically enhanced when combined with cytotoxic drugs in prostate cancer cells and tumor xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.141

Combination of gemcitabine and Ad5/3-Delta24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.141

Delta-24 increases the expression and activity of topoisomerase I and enhances the antiglioma effect of irinotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.141

Apoptotic pathways in pancreatic ductal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.141

Delta24-hyCD adenovirus suppresses glioma growth in vivo by combining oncolysis and chemosensitization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.141

Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.141

E1B55K-deleted adenovirus (ONYX-015) overrides G1/S and G2/M checkpoints and causes mitotic catastrophe and endoreduplication in p53-proficient normal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.141

An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.141

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifying the safety profile of a novel infectivity-enhanced conditionally replicative adenovirus, Ad5-delta24-RGD, in anticipation of a phase I trial for recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.141

inferred from DOI database lookup

7 January 2021

based on heuristic

Two phase I studies of concurrent radiation therapy with continuous-infusion 5-fluorouracil plus epirubicin, and either cisplatin or irinotecan for locally advanced upper gastrointestinal adenocarcinomas

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.141

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/GT.2011.141

1 reference

12 September 2017

1 reference